Organization · Venture Capital
Criteria Bio Ventures
Criteria Bio Ventures is a life sciences venture fund based in Barcelona, focusing on private biotech companies in Europe and North America, particularly Spain and Portugal. The fund aims to support transformative healthcare innovations addressing significant unmet medical needs.
Overview
What Criteria Bio Ventures does
What Criteria Bio Ventures is
Criteria Bio Ventures is a life sciences venture fund based in Barcelona, focusing on private biotech companies in Europe and North America, particularly Spain and Portugal. The fund aims to support transformative healthcare innovations addressing significant unmet medical needs.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- April 29, 2026
Official channels
Find Criteria Bio Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Criteria Bio Ventures as a funder
Investment thesis
Criteria Bio Ventures invests in private biotech companies developing disruptive, well-protected innovations for significant unmet medical needs. The firm provides evergreen support across various therapeutic modalities and disease areas, particularly in Europe and North America.
Focus narrative
The fund invests across various therapeutic modalities and disease areas, focusing on disruptive and well-protected innovations in the Life Sciences sector. Criteria Bio Ventures aims to provide continuous support to portfolio companies until they achieve meaningful impact, ensuring that they can navigate the complexities of biotech development.
Value beyond capital
Criteria Bio Ventures adds value to its portfolio companies by providing strategic, long-term support throughout their development journey. The firm leverages its extensive network within the life sciences sector to facilitate partnerships, funding opportunities, and access to expertise, ensuring that companies are well-positioned to achieve their clinical and commercial goals.
Focus and fit
- Stages
- Series A · Series B
- Sectors
- Biotech · Healthcare · Diagnostics
- Regions
- EuropeNorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 6
- Recorded notable exits
- Sanifit and Northern Biologics
Portfolio context
Aboleris Pharma: Developing a novel immunotherapy for autoimmune diseases. Sanifit: Acquired by Vifor Pharma, specializing in calcification disorders. Northern Biologics: Focused on cancer treatment, with assets acquired by Boehringer Ingelheim and AstraZeneca. Minoryx Therapeutics: Co-led Series C funding round, focusing on rare diseases. Adaptam Therapeutics: Disrupting myeloid immunosuppression in cancer with glyco-immune checkpoints. Aelix: Developing a new therapeutic HIV vaccine aimed at healing and eradication strategies.
Common questions
What to know about Criteria Bio Ventures
Upseed classifies Criteria Bio Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 29, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.